Daraxonrasib targets the KRAS mutation and extended median survival from 6.7 to over 13 months in nearly 500 patients with advanced pancreatic cancer.
Browsing: daraxonrasib pancreatic cancer survival
Daraxonrasib targets the KRAS mutation and extended median survival from 6.7 to over 13 months in nearly 500 patients with advanced pancreatic cancer.